↓ Skip to main content

Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial

Overview of attention for article published in BMC Cancer, September 2022
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
1 Dimensions

Readers on

mendeley
25 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial
Published in
BMC Cancer, September 2022
DOI 10.1186/s12885-022-09895-5
Pubmed ID
Authors

Abolghasem Allahyari, Ali Ehsanpour, Behrouz Najafi, Nafiseh Ansarinejad, Valiollah Mehrzad, Behjat Kalantari, Jahangir Raafat, Mojtaba Ghadiany, Farhad Shahi, Behrooz Gharib, Vahid Moazed, Adnan Khosravi, Mir Hossein Mirpour, Sina Salari, Seyedmohammadreza Mortazavizadeh, Amirabbas Nekoyi, Mohsen Khani, Alireza Sadeghi, Sirus Gharib, Alireza Bary, Mehrzad Mirzania, Shirin Haghighat, Seyed Mohsen Razavi, Seyed Amir Hossein Emami, Mehran Hosseinzadeh, Mahdi Mirbolouk, Sanambar Sadighi, Abdolali Shahrasbi, Ali Esfahani, Masoumeh Gity, Nassim Anjidani, Hamidreza Kafi, Safa Najafi

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 25 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 4 16%
Student > Bachelor 2 8%
Professor 2 8%
Other 1 4%
Lecturer 1 4%
Other 3 12%
Unknown 12 48%
Readers by discipline Count As %
Medicine and Dentistry 5 20%
Nursing and Health Professions 2 8%
Environmental Science 1 4%
Pharmacology, Toxicology and Pharmaceutical Science 1 4%
Biochemistry, Genetics and Molecular Biology 1 4%
Other 2 8%
Unknown 13 52%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 September 2022.
All research outputs
#20,693,952
of 23,292,144 outputs
Outputs from BMC Cancer
#6,593
of 8,437 outputs
Outputs of similar age
#345,986
of 435,405 outputs
Outputs of similar age from BMC Cancer
#141
of 228 outputs
Altmetric has tracked 23,292,144 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,437 research outputs from this source. They receive a mean Attention Score of 4.4. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 435,405 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 228 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.